Get started
III

InMed Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Seasonals

INM chart


Full chart

INM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.04 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.72 USD
Net income (FY)
‪−7.68 M‬ USD
Revenue (FY)
‪4.60 M‬ USD
Shares float
‪3.30 M‬
Beta (1Y)
2.88

Employees


Employees (FY)
13
Change (1Y)
0
Revenue / Employee (1Y)
‪353.67 K‬ USD
Net income / Employee (1Y)
‪−590.43 K‬ USD

About InMed Pharmaceuticals Inc.


Sector
Health Technology
CEO
Eric A. Adams
Headquarters
Vancouver
Website
inmedpharma.com
Founded
1981
FIGI
BBG000BT4589
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

INM news



Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of INM is 4.65 USD — it has decreased by −2.76% in the past 24 hours. Watch InMed Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange InMed Pharmaceuticals Inc. stocks are traded under the ticker INM.
INM stock has fallen by −15.74% compared to the previous week, the month change is a −8.04% fall, over the last year InMed Pharmaceuticals Inc. has showed a −41.99% decrease.
INM reached its all-time high on Jan 8, 2018 with the price of 32,178.22 USD, and its all-time low was 2.41 USD and was reached on Aug 6, 2024. View more price dynamics on INM chart.
See other stocks reaching their highest and lowest prices.
INM stock is 22.00% volatile and has beta coefficient of 2.88. Track InMed Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is InMed Pharmaceuticals Inc. there?
Today InMed Pharmaceuticals Inc. has the market capitalization of ‪14.08 M‬, it has decreased by −16.73% over the last week.
Yes, you can track InMed Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
InMed Pharmaceuticals Inc. is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
INM net income for the last quarter is ‪−1.68 M‬ USD, while the quarter before that showed ‪−1.94 M‬ USD of net income which accounts for 13.41% change. Track more InMed Pharmaceuticals Inc. financial stats to get the full picture.
No, INM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 13.00 employees. See our rating of the largest employees — is InMed Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. InMed Pharmaceuticals Inc. EBITDA is ‪−6.93 M‬ USD, and current EBITDA margin is −163.77%. See more stats in InMed Pharmaceuticals Inc. financial statements.
Like other stocks, INM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade InMed Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So InMed Pharmaceuticals Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating InMed Pharmaceuticals Inc. stock shows the sell signal. See more of InMed Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.